Home / Health / Oxford Covid-19 vaccine trials in India: Serum Institute seeks DCGI nod

Oxford Covid-19 vaccine trials in India: Serum Institute seeks DCGI nod

Initial results of the first two-phase trials of the vaccine conducted in five trial sites in the UK showed it has an acceptable safety profile and homologous boosting increased antibody responses

covid, coronavirus, vaccine, drug, pharma

Premium

These vaccines will be for India and middle and low income countries across the world (GAVI countries), he had said.

2 min read Last Updated : Jul 25 2020 | 5:07 PM IST

Serum Institute of India (SII), which has partnered with AstraZeneca for manufacturing the Oxford vaccine candidate for Covid-19, has sought permission from the Drugs Controller General of India (DCGI) for conducting phase 2/3 human clinical trials of the potential vaccine, highly-placed sources said on Saturday.

The sources told PTI that the Pune-based drug firm submitted its application to the DCGI on Friday seeking permission for conducting the trials of ''Covidshield''.

"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of ''Covishield'' (Covid-19) in healthy Indian adults. The firm said that an

Topics : Serum Institute of India Coronavirus Vaccine Drug Controller General of India

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in